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Epidermal growth factor receptor (EGFR)
Protein trafﬁcking
Ubiquitination
EndosomeHuntingtin (htt) is a scaffold protein localized at the subcellular level and is involved in coordinating the
activity of several protein for signaling and intracellular transport. The emerging properties of htt in intracel-
lular trafﬁcking prompted us to study the role of mutant htt (polyQ-htt) in the intracellular fate of epidermal
growth factor receptor (EGFR), whose activity seems to be strictly regulated by htt. In particular, to evaluate
whether protein trafﬁcking dysfunction occurs in non-neuronal cells in the absence of functional htt, we
monitored the EGFR protein in ﬁbroblasts from homozygotic HD patients and their healthy counterpart.
We found that polyQ-htt controls EGFR degradation and recycling. Lack of wild‐type htt caused alteration
of the ubiquitination cycle, formation of EGFR-incorporating high-molecular weight protein aggregates and
abnormal EGFR distribution in endosomes of the degradation and recycling pathways after EGF stimulation.
PolyQ-htt-induced alteration of EGFR trafﬁcking affected cell migration and proliferation, at least in part,
through inhibition of ERK signaling. To our knowledge the data here reported represent the ﬁrst signaling
and phenotypic characterization of polyQ-htt involvement in the modulation of growth factor stimulation
in non-neuronal cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is an inherited neurodegenerative dis-
ease caused by expansion of cytosine–adenine–guanine (CAG) repeats
in the 5′ region of the IT15 gene that encode polyglutamine (polyQ)
tracts within the 350-kDa protein called huntingtin (polyQ-htt) [1].
Huntingtin plays a role in protein trafﬁcking, vesicle transport, postsyn-
aptic signaling, transcriptional regulation, and apoptosis [2,3]. Thus, a
loss of function of the normal protein and a toxic gain of function of
mutant htt contribute to disruption of multiple intracellular pathways.
Although the disease is mainly manifested as a neurodegenerative
disease it is also true that the systemic symptoms are very common
and often overlooked [4]. Indeed, HD ﬁbroblasts have deﬁcits in reg-
ulatory functions that are seen in neural tissues, including impairedistry, CNR, Via Pietro Castellino,
rights reserved.proteasome activity [5] and abnormal cholesterol synthesis [6]. More-
over, in HD ﬁbroblasts the movement of early endosomes is altered as
are the levels of catalase, which is associated with the regulation of
oxidative stress [7,8].
These biological ﬁndings are possibly caused by polyQ-htt which
is ubiquitously expressed in neuronal as well as in non-neuronal
cells [9,10]. It has been hypothesized that polyQ-htt binds aberrantly
to individual interacting partners and, consequently, the function of
the speciﬁc interacting partner is affected [11]. Indeed, in gel ﬁltration
and Western blot studies conducted under non-denaturing condi-
tions, htt migrates in a large (>1000-kDa) complex, which raises
the possibility of many direct or indirect interacting proteins [12].
Among these potential htt-interacting proteins, the epidermal growth
factor receptor (EGFR), whose signal transduction seems to be medi-
ated by wild-type htt, is particularly interesting [13]. However, very
little is known about how polyQ-htt interferes with EGFR signaling.
Moreover, no one has studied yet the correlation between the pres-
ence/formation of aggregates and interference with EGFR signaling.
In this study, we used a model of non-neuronal cells (primary cul-
tures of ﬁbroblasts from healthy subjects and from homozygotic HD
patients) to investigate the effects of polyQ-htt versus wild-type htt
loss in modulating the fate of internalized EGFR after EGF stimulation,
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complex in HD pathogenesis.
2. Materials and methods
2.1. Antibodies and reagents
Antibodies anti-PY-845, -1045, -1086, -1148, and ‐1173 EGFR,
antibody anti-phospho ERK 1/2 and horseradish peroxidase
(HRP)-conjugated secondary antibodies were purchased from Cell
Signaling Technology (Milan, Italy). Antibodies anti-PY-992 and ‐1068
EGFR were from Biosource (Milan, Italy). Anti-CbI pAb and 528-
PEconjugated mouse anti-EGFR, anti-ERK-1(C-16) and anti-huntingtin
(C-terminal region, rabbit polyclonal)were fromSanta Cruz Biotechnol-
ogy (Milan, Italy). Anti-tubulin was purchased from Sigma-Aldrich
(Milan, Italy). Anti-EGFR pAb was purchased from Upstate (Milan,
Italy). HRP-conjugated mouse anti-PY (PY20) was purchased from
BD Transduction Labs. Anti-transferrin receptor 1 (phospho S24)
antibody was purchased from Abcam (Italy), and Cy3- and FITC-
conjugated secondary antibodies were from Jackson Immunoresearch
Labs (Milan, Italy). Anti-EEA1 (rabbit polyclonal), anti-LAMP-1 and ‐2
(rabbit polyclonal) and anti-Rab-11 (rabbit polyclonal)were purchased
from Abcam, (Milan, Italy). Anti-polyQ antibody was from Chemicon
Int. (Millipore, Milano, Italy). Dulbecco's modiﬁed Eagle's medium
(DMEM), fetal calf serum (FBS) and tissue culture reagents were pur-
chased from Hyclone, Milan, Italy. All other chemicals of reagent grade
were obtained from Sigma-Aldrich chemical Co. (Milan, Italy).
2.2. Fibroblast cultures
Primary ﬁbroblasts were obtained from human skin biopsies of
both HD homozygote patients (number patients, ages and CAG repeats
in parentheses) (n=3; two males and one female, 47 years, 42/44;
53 years, 39/42; 51 years, 40/44 CAG repeats, mean age=50) and 3
age-matched healthy subjects (n=3, one male and two females,
mean age=51) who underwent elective surgery unrelated to the
study. All patients were symptomatic when the skin biopsy was done.
Primary human ﬁbroblast cells were grown in DMEM supplemented
with 10% FBS, 50 U/ml penicillin, 50 mg/ml streptomycin, and
2 mM L-glutamine in a humidiﬁed atmosphere of 5% CO2 at 37 °C.
The number of passages was less than 5 for all ﬁbroblast cultures. All
human materials were processed according to the recommendations
of the local Ethics Committee and Security Board including informed
consent and in accordance with the Declaration of Helsinki on ethical
principles for medical research involving human subjects.
2.3. Cell migration assay and wound assay
Cell migration was investigated using a modiﬁed Boyden chamber
assay. The experiments were done in triplicates; 5 ﬁelds of each ﬁlter
were counted. Basal and EGF-induced migration was assessed by the
ability of the cells to move into an acellular area [14]. Photographs
were taken at 0 and 24 h, and the distance traveled by the cells at
the acellular front was determined. Mitomycin C (10 mg/ml) was
added to the cells for 2 or 16 h before scraping, rinsed with PBS to re-
move mitomycin C, and carried out as described above. Images were
superimposed with a 0.3 mm×0.3 mm grid to quantify wound clo-
sure. Percent wound closure was calculated by comparing the number
of grids in the deﬁned wound area not occupied by cells after each
time interval.
2.4. Proliferation assay
Cells were plated in 96-well dishes (5×103/well) under non-
permissive proliferation conditions (complete medium containing 0.5%
FBS). Cultures were exposed to EGF or vehicle for 24 h. Cells werecounted at 0 and 24 h using an MTT-based colorimetric proliferation
assay kit (Promega, Milan, Italy). Reported values reﬂect averages of at
least 12 replicate wells.
2.5. Western blotting and immunoprecipitation
Aliquots, 7.5 μg of protein, of the total cell lysate from control and
htt-expressing cells, treated or notwith EGFor transferrin for different pe-
riods of timewere analyzed by either SDS-5%PAGEor SDS3–12%gradient
PAGE after determining protein concentrations using a bicinchoninic acid
(BCA) kit (Pierce,Milan, Italy). Proteinswere blotted onto a nitrocellulose
ﬁlter, and stained with primary antibodies and horseradish peroxidase-
conjugated anti-mouse IgG antibody as secondary antibody using an
enhanced chemiluminescent (ECL) chromogenic reagent kit. The blots
were exposed to Kodak X-Omat ﬁlm, and protein band intensity was
measured using a Chemidoc XRF (Bio-Rad Italia, Italy) and Quantity One
version 4.6.3 software (Bio-Rad Italia, Italy).
For immunoprecipitation experiments, 200 μg of protein lysate
(1 mg/ml) was added to Sepharose-anti‐EGFR beads solution and
the mixture was incubated for 1 h at 37 °C. The incubated lysate
was centrifuged at 2000g for 2 min at RT. The pellet was washed
three times in TBS with 0.1% Tween 20 and centrifuged at 3000g
for 2 min. Then, 50 μl of loading buffer (50 mM Tris–HCl, pH 6.8, 5%
β-mercaptoethanol, 0.2% SDS, 0.1% bromophenol blue, 10% glycerol)
was added to the washed pellet. Western blotting was performed
on the ﬁnal immunoprecipitation lysate. Membranes were probed
either with the EGFR mAb, to conﬁrm the detection of EGFR species,
or with the polyQ-htt mAb, to detect molecular interaction between
polyQ-htt and EGFR.
2.6. EGFR internalization assay
EGFR endocytosis rates were determined as previously described
[15]. Cultures were washed and treated with 10 ng/ml biotin-labeled
EGF (Invitrogen) in PBS with 0.9 mM CaCl2, 0.5 mM MgCl2, and 5 mM
glucose, followed by acid wash in 125 mM NaCl, 25 mM acetic acid, pH
3, to strip off surface-bound EGF. Cells were ﬁxed in PBS containing 3%
paraformaldehyde, 0.25% glutaraldehyde, and 0.25% Triton X-100, treat-
ed with 50 mM glycine, blocked, and incubated with streptavidin–HRP.
Internalized HRP was detected by o-phenylenediamine dihydrochloride
absorbance at 450 nm. Absorbance data of EGFR internalization were
normalized by protein concentration in cell lysates, as detected by
bicinchoninic acid (BCA) kit (Pierce, Milan, Italy).
2.7. Recycling, degradation, and intracellular distribution assays
125I-EGF and 125I-transferrin assays were performed as previously
described [16,17]. Brieﬂy, cells were washed with binding medium
(DMEM with 20 mM HEPES, 0.1% bovine serum albumin, pH 7.3) and
treated with 10 ng/ml 125I-EGF or 10 ng/ml 125I-transferrin in binding
buffer for 1 h at 4 °C. Media containing unbound ligand were removed
and collected. The cells werewashed four timeswith ice-cold PBS. Fresh
pre-warmed, 37 °C media containing non-radioactive EGF or transfer-
rinwere added and cells were returned to 37 °C for the indicated period
of times. The amount of intracellular ligand was calculated as a fraction
of total cell associated radioactivity by TCA precipitation of intact
radioligand.
Recycled EGF or trasferrin was evaluated following incubation of
cells in glycine buffer solution (pH 3.5) to release cell surface‐bound
EGF or transferrin. The amount of released EGF or transferrinwas deter-
mined as a fraction of total released radioactivity by TCA precipitation.
To assess EGF or transferrin degradation, cells were washed in cold
binding buffer (DMEM supplemented with 25 mM HEPES, pH 7.4, and
2 mg/ml BSA) and incubated at 4 °C for 1 h with 10 ng/ml 125I-EGF or
10 ng/ml 125I-transferrin. Then, the cells were incubated at 37 °C in
binding buffer without 125I-EGF or 125I-transferrin for the indicated
Fig. 1. Phosphorylation and internalization of EGFR in control and polyQ-htt expressing cells.
(A) PolyQ-htt expression does not interrupt ligand-driven phosphorylation of EGFR. Cell cul-
tureswere stimulatedwithdifferent concentrations of EGF for 5 min.Westernblot analysis of
cell lysates was carried out by anti-PY for EGFR phosphorylation. The bar graph is quantiﬁca-
tion by scanning densitometry of the degree of tyrosyl phosphorylation of the EGFR normal-
ized on EGFR levels. The values represent the mean of duplicate determinations from three
chemiluminescence ﬁlms exposed in the linear range. (B) PolyQ-htt expression does not in-
terfere with EGFR internalization. Control and polyQ-htt expressing cells were exposed to
biotin-labeled EGF for the indicated times, and processed as described in “Materials and
methods.” The absorbance data of EGFR internalization were normalized by protein concen-
tration in cell lysates, as detected by bicinchoninic acid (BCA) kit (Pierce,Milan, Italy). No sig-
niﬁcant decreases (all P>0.05) were observed in polyQ-htt expressing cells compared with
control cells. (C) Western blot ﬁlm of data presented in (A).
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examined by trichloroacetic acid precipitation of intact radioligand and
by assaying for the presence of 125I in culture media.
Analysis of radioligand distribution was performed using a Percoll
gradient [16]. Data were plotted at the percentage of total radioactivity
in each tube versus the relativemigration of each fraction in the sample.
For each experiment, a parallel tube of 17% Percoll containing density
marker beads was run to monitor relative density. Some fractions
(150 μl) were resolved by SDS-PAGE. After transfer to nitrocellulose,
the resultingmembranewas blotted with LAMP1 (lysosome-associated
membraneprotein-1) andEEA1 (early endosomeantigen-1) antibodies.
EGFR turnover was also analyzed by using [35S]-methionine using
a method already described [18].
2.8. LC-MS/MS analysis of EGFR ubiquitination
To examine the ubiquitination pattern of the EGFR in cells that
express polyQ-htt, the ubiquitin-AQUA method was used [19]. Brieﬂy,
control and polyQ-Htt cells were grown in 150 mm dishes and treated
or untreated with 10 ng/ml EGF for 5 min at 37 °C. Lysates were gener-
ated by the addition of TGH solubilization buffer (Triton X-100/glycerol/
HEPES) containing 1% sodium deoxycholate (DOC) and 10 mM N-
ethylmaleimide. EGFR was immunoprecipitated by a monoclonal EGFR
antibody. After sequential washes with TGH/DOC buffer containing
500 mM, 100 mM and without NaCl, samples were separated by SDS-
PAGE and analyzed bymass spectrometry using isotope-labeled internal
standard peptides as previously described [19].
2.9. Signaling and EGFR degradation assays
Erk1/2 activation and EGFR degradation were measured in cells
serum-starved. Cells were incubated in the presence of EGF (10 ng/
ml) at 37° C for different time points, washed with ice-cold PBS and
lysed as described above. Proteinswere separated by SDS-PAGE and an-
alyzed by Western blotting phospho-Erk1/2 and EGFR antibodies. ERK
phosphorylation was normalized by using an anti-ERK1 antibody.
2.10. Statistical analysis
All statistical analyses were performed using GraphPad software
(Prism 4.0). Signiﬁcance was determined using two-way analysis of
variance followed by Bonferroni's multiple comparison test. Values
of Pb0.05 were considered signiﬁcant.
3. Results
3.1. EGF-dependent phosphorylation and internalization of EGFR in control
and polyQ-htt cells
To determine if expression polyQ-htt causes down-expression of
EGFR, a 125I-EGF binding assay was performed.We found that the aver-
age number of 125I-EGF binding sites in three primary cell cultures of
HD patient ﬁbroblasts was 1.3×105±0.2 receptors per cell versus
1.1×105±0.1 receptors per cell in the controls. The dissociation con-
stants determined by Scatchard analysis was not signiﬁcantly different
between the control and polyQ-htt-expressing cells, which indicates
that polyQ-htt did not appreciably change the afﬁnity of EGFR for EGF.
We performed a western blot analysis to compare EGFR level in HD
and controls. We did not evidence signiﬁcant differences (Suppl. Fig. 3).
To verify that also the EGFR phosphorylation was not signiﬁcantly
affected by polyQ-htt, quiescent cells were exposed for 5 min to 10
or 100 ng/ml EGF. Control and polyQ-htt-expressing cells, in the ab-
sence of exogenous EGF, showed very low EGFR phosphorylation
(Fig. 1A–C; Suppl. Table 1). Moreover, polyQ-htt expression did not at-
tenuate rapid EGF-stimulated EGFR activation, as determined by over-
all receptor tyrosine phosphorylation. When the blots were quantiﬁedby scanning densitometry, the degree of EGFR phosphorylation in
polyQ-htt-expressing cells upon EGF challenge followed a pattern sim-
ilar to that of controls (Fig. 1A–C; Suppl. Table 1). To further verify if
polyQ-htt did not affect speciﬁc EGFR phosphorylation, we determined
the pattern of EGFR tyrosine phosphorylation induced by EGF stimula-
tion using a panel of site-speciﬁc antibodies, each speciﬁc for phos-
phorylation of EGFR residues Tyr-845, Tyr-992, Tyr-1045, Tyr-1068,
Tyr-1086, Tyr-1148 and Tyr-1173. There were no differences between
the EGF-induced tyrosine phosphorylation of EGFR in control and
polyQ-htt-expressing cells (Suppl. Fig. 1). To further evaluate the effect
of polyQ-htt, we analyzed the phosphorylation of transferring receptor
1 (TFR1) that is another membrane-bound receptor. We did not ob-
serve differences between the transferrin-induced serine phosphoryla-
tion of TFR1 in control and polyQ-htt-expressing cells (Suppl. Fig. 2).
To determinewhether polyQ-htt affected EGFR internalization rates,
we carried out quantitative internalization assays using biotin-labeled
EGF (Fig. 1B; Suppl. Table 1). Again, we found no evidence of altered
EGFR internalization in polyQ-htt-expressing cells.
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cells
To further probe the effect of polyQ-htt on EGFR endocytic trafﬁck-
ing, we measured the rate of EGF degradation and recycling (Fig. 2A
and b). Themeasurement of the extent of 125I-EGF degradation showed
that the amount of 125I radioactivity in polyQ-htt-expressing cells was
less than half as compared to control cultures (Fig. 2A; Suppl. Table 1).
On the contrary, the pH-sensitive binding of intact 125I-EGF to its cell
surface receptor was signiﬁcantly higher in control cells than in
polyQ-htt-expressing cells (Fig. 2B; Suppl. Table 1). Thus, control cells
recycled more intact growth factor to the cell surface, where it speciﬁ-
cally binds to its receptor. Notably, the lower rate of receptor degrada-
tion in polyQ-htt-expressing ﬁbroblasts was unrelated to a higher rate
of receptor recycling. To evaluate if the observed phenomenon was
speciﬁc for EGF-EGFR pathway, we measured the rate of transferrinFig. 2. Degradation and recycling of EGF and transferrin in control and polyQ-htt expressing cells. (
cells with 10 ng/ml 125I-EGF or 125I-transferrin for 1 h followed by incubation with non‐radioacti
degraded 125I-EGF (A) or 125I-transferrin (D) (soluble in 10% trichloroacetic acid, TCA). The cells
releasable by incubation at pH 3.5 and precipitable by TCA. Data shown (the mean±S.D.) wer
* Pb0.05 versus the control. (C) EGFR turnover was assayed by metabolically labeling the
immunoprecipitated following various chase periods and was quantiﬁed by densitometry of the
* Pb0.05 versus the control.degradation and recycling and found no signiﬁcant differences be-
tween polyQ-htt and control ﬁbroblasts (Fig. 2D and E).
The delayed degradation of EGFR was conﬁrmed by a pulse-chase
experiment following metabolic labeling of cells with [35S]-methionine
(Fig. 2C). These experiments indicated that, while control cells retained
~40% of the radiolabeled receptor after a 3-h chase, 80% of the radio-
labeled EGFR was still detectable in cells expressing polyQ-htt.
3.3. Effect of polyQ-htt on EGFR cell trafﬁcking after EGF stimulation
As a second approach to determine whether the proximal steps of
EGF-stimulated endocytic trafﬁcking were disrupted by polyQ-htt ex-
pression, we examined the cell distribution of the EGFR before and after
EGF treatment. In particular, we examined the distribution of EGFR in
early endosomes (EEA1-positive) and lysosomes (LAMP-2-positive) in
an attempt to obtain clues as to the site of EGFR recruitment after EGFA, B, D, and E)Degradation and recycling of EGF and transferrinwas determined after loading
ve ligand for the indicated periods of time. The medium and cell lysates were examined for
were analyzed for recycled cell surface (receptor-bound) 125I-EGF (B) or 125I-transferrin (E),
e from three lines of control ﬁbroblasts and three lines of polyQ-htt expressing ﬁbroblasts.
cells with [35S]methionine has described under “Materials and methods.” EGFR was
autoradiograms. The data are presented as means±S.D. of three independent experiments.
Fig. 3. Accumulation of EGFR in early endosomes by polyQ-htt expression. Control and polyQ-htt expressing cellswere incubatedwith 125I-EGF for 30 min at 37 °C,washedwith ice-cold PBS at
4 °C, incubated with DMEM-medium for an additional 45 min at 37 °C and harvested. Post-nuclear supernatant was separated over a 17% Percoll gradient. Fractions were collected from the
bottom (Rf 1.0) and assayed for associated radioactivity. Data are plotted as the relative migration through the Percoll gradient (x axis) versus the percentage of total radioactivity found in
each fraction (y axis). The fraction from gradient was resolved by a 7.5% SDS-PAGE and immunoblotted for either EEA1 or LAMP-2 to probe for the early endosome or lysosome, respectively
(bars on plotting). Dots above the x axis representmigration of density beads (Rf 0.3=1.040 g/ml; Rf 0.7=1.052 g/ml; Rf 0.85=1.055 g/ml; Rf 0.88=1.080 g/ml; Rf 0.91=1.109 g/ml). Below
the graph there are western blot data of representative fractions.
Fig. 4. PolyQ-htt inhibits EGFR ubiquitination and c-Cbl recruitment. Cells were incubated
with EGF for 5 min at 37 °C, and the association of EGFR and c-Cbl or ubiquitinwas deter-
mined by immunoprecipitation of EGFR andWestern blotting for c-Cbl or ubiquitin as de-
scribed under “Materials and methods.” Proteins, separated by SDS-PAGE, were probed
using antibodies speciﬁc for ubiquitin, EGFR, and c-Cbl. The bar graph was derived from
densitometric analysis of Western blots normalized to EGFR signal that direct compari-
sons could be made. The data are presented as means±S.D. of three independent exper-
iments (⁎Pb0.05).
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compartments in which 125I-EGF was internalized. Both control and
polyQ-htt expressing cells incubated with 125I-EGF for 15 min accumu-
lated 125I-EGF in light endosomes (density >1.035–1.040 g/ml; data
not shown). This is consistent with the fact that polyQ-htt does not affect
the endocytosis of the EGFR or movement to early endosomes. 125I-EGF
was distributed in a completely different way in control and polyQ-htt
expressing cells after 30 min of incubation (Fig. 3). In control cells, the
radioligand accumulated in high density endosomes (mean density
~1.080 g/ml). In polyQ-htt-expressing cells the radioligand peaked
again in light endosomes, while no signiﬁcant peak in 125I was seen in
high density endosomes. Individual fractions were probed for the pres-
ence of endosomal marker proteins, namely LAMP-2 (lysosome) and
EEA1 (early endosome), and again the data conﬁrm accumulation of
radioligandmostly in the light endosomal compartment in polyQ-htt ex-
pressing cells.
3.4. Inhibition of c-Cbl/EGFR interaction and EGFR ubiquitination by
polyQ-htt expression
It has been recently hypothesized that the E3 ubiquitin ligase c-Cbl
(Casitas B-lineage lymphoma protein) might control the endocytosis
and degradation of EGFR at a trafﬁcking checkpoint subsequent to
receptor internalization en route lysosomes [20]. Therefore, we ana-
lyzed the interaction between c-Cbl and EGFR in cells stimulated for
5 min with EGF using an experimental procedure in which immuno-
precipitation of cell lysates with anti-EGFR was followed by Western
blotting with anti-Cbl antibody. Complex formation was detected be-
tween c-Cbl and EGFR in control cells, but at very low level in polyQ-
htt cells, which demonstrates that polyQ-htt expression inhibits EGF-
stimulated recruitment of c-Cbl to the EGFR (Fig. 4 and Suppl. Fig. 4).
Since ubiquitination of EGFR is also mediated by c-Cbl [21], both
directly via EGFR-SH2 domain interactions, and indirectly via a second
adaptor protein, Grb2 [22], we investigated if the interaction of EGFR
with c-Cbl disrupted by polyQ-htt could affect EGFR ubiquitination.
Indeed, signal transducing receptors such as the EGFR are commonly
ubiquitinated following activation as part of the mechanism for tar-
geting to the lysosomal or proteosomal-degradative pathways [22].
The results shown in Fig. 4 highlighted that EGFR ubiquitination is re-
duced by >70% when polyQ-htt is expressed.Our ﬁnding, that ubiquitination of activated EGFR is signiﬁcantly
decreased in cells expressing polyQ-htt, led us to investigate whether al-
terations in the type of receptor ubiquitination occurred as well. Using
the ubiquitin-AQUA method to quantify the forms of polyubiquitin
bound to the EGFR [19], we demonstrated that polyubiquitin chains
linked through Lys-63 were more abundant than all the other linkages,
comprising almost 37% of the total EGFR ubiquitination both in control
and polyQ-expressing cells. Moreover, Lys-48 linkage was also identi-
ﬁed, representing ~11% of the ubiquitinated EGFR. The other ubiquitin
forms (i.e. Lys-29, -11, -6, -27, and ‐33) were practically undetectable.
Therefore, despite suppressed ubiquitination, the nature of the ubiquitin
linkage for EGFR in polyQ-htt expressing cells was nearly identical to
that observed in control cells.
Fig. 5. Time-dependent variations of intracellular EGFR level after long‐termEGF stimulation.
Cells were stimulated with 10 ng/ml EGF for 6 h and lysed in buffer. (A) Whole cell lysates
from control (lanes 1 and 2) and polyQ-htt expressing cells (lanes 3 and 4) were probed
with anti-EGFR antibody before (lanes 1 and 3) and after (lanes 2 and 4) EGF stimulation.
(B) Control (lanes 1 and 2) and polyQ-htt expressing cells (lanes 3 and 4) were cultured
without (lanes 1 and 3) or with EGF for 6 h (lanes 2 and 4), andwhole cell lysates were pre-
pared and immunoprecipitated with anti-EGFR antibody. Western blotting was performed
on the ﬁnal immunoprecipitation lysate. Membranes were probed with the anti-C-terminal
htt antibody (lanes 1–4) or with anti-polyQ-htt antibody (lanes 5 and 6) to detect
molecular interaction between polyQ-htt and EGFR. (C) Western blot of tubulin as loading
control for samples of (B). Molecular weight standards (in kDa) are indicated on the left. Ar-
rows indicate the origin of electrophoresis. These results have been replicated at least ﬁve
times for each cell line and representative blots are shown.
Fig. 6. Inhibitionof ERKactivationbypolyQ-htt expression. Control andpolyQ-htt expressing
cells were either left untreated (−EGF) or stimulated with 10 ng/ml of EGF for 5, 30 and
120 min. Cells were lysates and proteins were separated on 11% SDS-PAGE and
immunoblotted with either anti-phospho-ERK1/2 (pERK1/2) or anti‐ERK1/2, as indicated.
Tubulin was used as loading control. The level of total ERK1/2 were normalizedwith tubulin
and then used to evaluate the level phospho-ERK1/2. These results have been replicated at
least ﬁve times for each cell line and representative blots are shown. *Pb0.05.
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It is well documented that long-term EGF stimulation induces
down-regulation of EGFR [23]. We used immunoblotting of total cell ly-
sates to estimate the abundance of the EGFR in control and polyQ-htt
expressing cells treatedwith EGF over a 6 h period (Fig. 5). As expected,
continuous exposure to EGF caused the amount of EGFR in control cells
to decline to ~10% of initial levels (Fig. 5A, lanes 1 and 2). PolyQ-htt
expression substantially attenuated EGFR down‐regulation. Indeed,
total EGFR decreased to only ~40% versus resting cells (Fig. 5, lanes 3
and 4). Interestingly, an additional high‐molecular weight (HMW)
EGFR-immunoreactive band appeared in polyQ-htt expressing cells at
the interface between the stacking and running gels (Fig. 5, lanes 3
and 4). The intensity of this band increased after incubation of cells
with EGF. Densitometric analysis ofwestern blots revealed a 5.4-fold in-
crease in HMW-EGFR from 6 to 24 h of incubation with EGF (data not
shown). Treatment with the protein synthesis inhibitor cycloheximide
(10 mg/ml, 1 h pre-treatment) did not affect the polyQ-htt-mediated
protection from EGF-induced EGFR loss.
To evaluate whether HMW-EGFR-immunoreactive band could re-
sult from abnormal interaction between EGFR and polyQ-htt, theimmunoprecipitation of cell lysates with anti-EGFR was followed by
Western blotting with anti-polyQ-htt antibody. Again, we detected a
high‐molecular weight band, which was recognized by the anti-htt an-
tibody only in polyQ-htt expressing cells (Fig. 5B, lanes 3 and 4). The
same results were obtained using antibodies against polyQ expansion
(Fig. 5B, lanes 5 and 6). Interestingly, HMW-EGFR-immunoreactive
band increased after EGF stimulation (Fig. 5, lane 4).
3.6. EGF-induced ERK1/2 phosphorylation in the control and polyQ-htt
expressing cells
The alteration in EGFR endocytic process in polyQ-htt cells we ob-
served may affect the EGF-related pathways with important conse-
quences on cell biology. This prompted us to investigate the ERK1/2
(ERKs) pathway, which is a well-established and important molecular
target downstream EGF receptor [24,25]. Thus, we analyzed ERK phos-
phorylation following EGF stimulation in ﬁbroblasts obtained from HD
patients as compared to control ﬁbroblasts (Fig. 6). We found that in
control cells, ERKs is phosphorylated upon EGF treatment. The phos-
phorylation of ERKs was persistent and still high after 30 min following
EGF stimulation, while it decreased to the basal level after 120 min. On
the contrary, in cells expressing polyQ-htt after 5 min following EGF
stimulation the phosphorylation of ERKs was signiﬁcantly lower than
control cells (Fig. 6). In addition, when we carried out a kinetic, we ob-
served that in polyQ-htt expressing cells, ERK phosphorylation appears
transient since it returns to baseline after 30 min of EGF stimulation.
3.7. Altered EGFR trafﬁcking affects cell migration and cell proliferation in
the polyQ-htt expressing cells
EGF receptor is involved in cell proliferation and motility via ERK
pathway in several cellular systems [26–29]. The modiﬁcation of endo-
cytic trafﬁcking of the EGFR and of ERK activation in polyQ-htt cells sug-
gests that control cell migration and proliferation may be affected in
presence of polyQ-htt. This hypothesis is in line with pioneering re-
search showing thatﬁbroblast cultures from twoHDpatients evidenced
alteration in cell density and proliferation [30]. To correlate EGFR traf-
ﬁcking data with cellular response, we quantiﬁed both cell migration
and cell proliferation in the control and polyQ-htt-expressing cells. To
Fig. 7. Cell migration and proliferation assays. (A) Transwell migration assaywas performed
using 5-mm pore, 6.5 mm polycarbonate transwell ﬁlters. Suspensions of control and
polyQ-htt expressing cells were seeded onto the upper surface of the ﬁlter and allowed to
migrate toward the bottom of the transwell, which contained or not 10 ng/ml of EGF. After
24 h of incubation, cells that migrated to the underside of the ﬁlter were ﬁxed, stained
with 0.5% crystal violet, and counted by bright ﬁeld microscopy at ×200 magniﬁcation in
ﬁve random ﬁelds. Each data point represents the mean±S.D. of ﬁve different experiments.
*Pb0.05. (B) In vitro wound healing assay. Cells were plated on a 24-well plastic dish and
grown to conﬂuence in DMEM with 10% FBS. After quiescence for 24 h in medium with
0.5% dialyzed FBS, a sterile tip was used to scratch wounds through the cell monolayer.
After wounding, cells were grown in culture media containing 1% horse serum±10 ng/ml
EGF. In all the experiments,mitomycin Cwas present throughout the experiment to counter-
act the effects of cellular proliferation. Thewound closure (with±S.D. values,n=9) indicates
the percentage gap between thewound edges at 24 h relative to time 0. The surface areas of
the initial wound (set at 100%) and at the end of treatment were recorded with time-lapse
video microscopy and measured by Image Analysis software. Nine wounds were studied
for each treatment group. (C) Control and polyQ-htt expressing cells were plated in
96-well dishes (5×103/well) and then exposed to EGFor vehicle for 24 h. Cellswere counted
at 0 and 24 h using an MTT-based colorimetric proliferation assay. Reported values reﬂect
averages of at least 12 replicate wells. *Pb0.05.
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gration, we performed in vitro migration and wound healing assays
(Fig. 7A and B). Compared with control cells, the expression of polyQ-
htt resulted in reduced cell motility in Boyden chamber (Fig. 7A). In
wound assays experiments, control cells migrated into the wound and
completely reconnected the disrupted monolayer by 24 h. The polyQ-
expressing cells did not close the wound at 24 h. These differences in
cell migrationwere observed as early as 6 h post-wounding and drastic
differences were observed at 10 h. Importantly, migration of polyQ-
expressing cells occurred before a signiﬁcant effect on cell proliferation
was evident, indicating that the observed difference in migration was
not simply due to a difference in proliferation rates. Moreover, theaddition of mitomycin C did not affect the ability of control cells to
close the wound, which demonstrates that the results of the wound as-
says were due to an EGF-induced increase in cell motility and not to an
enhanced rate of EGF-induced induced proliferation.We also quantiﬁed
themigration of cells in this assay to obtain ameasure of cellmotility. As
shown in Fig. 7B, there was an increase of more than twofold in migra-
tion of control cells at 6 h and greater than three-fold increase at 10 and
24 h.
We next measured cell proliferation by MTT assay 25 h after li-
gand stimulation (Fig. 7C). Again, there was a signiﬁcant difference
(i.e., Pb0.05 in all cases) between the two cell types in terms of cell
proliferation. Thus, polyQ-htt expression did inhibit the proliferation
in all of the conditions probed.
4. Discussion
Activation of EGFR signaling is started by receptor dimerization
and tyrosine autophosphorylation and can induce, after activation of
ERK1/2, several biological effects such as cell proliferation or migration.
Although studies investigating EGFR signaling in HD are limited, there
are evidence of an involvement of polyQ-htt inmodulation of EGF activ-
ity. In a Drosophila study, mutant htt disrupted EGFR/RAS/ERK signaling
in glial cells, and reduced signaling through this pathway was associat-
ed with inclusion formation and reduced life span [31]. The potential
role of polyQ-htt-induced alteration in EGFR signaling in pathogenesis
of cell dysfunction is exempliﬁed by the PC12 cell model. Using PC12
cells expressing a mutant htt, it has been demonstrated that mutant
htt antagonizes EGFR activity [32], leading to disruption of cellular
signaling and biological function mediated by EGF, such as cell
proliferation.
However, the molecular mechanisms underlying the disorder in-
duced by polyQ-htt on EGFR signaling, both in neuronal and non-
neuronal cells, remains to be clariﬁed. One possibility is that polyQ-htt
impairing EGFR intracellular trafﬁcking can inhibit EGFR signaling. In-
deed, htt, which has been localized to Golgi vesicles [33], early endo-
somes [34], recycling endosomes [8], and lysosomes [35], strongly
regulates the bidirectional endosomal trafﬁcking and transport inmam-
malian cells.
The distinct steps of endosomal protein trafﬁcking are today well
deﬁned. After binding with the ligands, receptors are taken up from
the plasma membrane into endocytic vesicles that mature into early
endosomes and undergo dynein-dependent sorting and movement
toward the cell center [36]. From the early endosome, some cargoes
are delivered to recycling endosomes for return to the plasma mem-
brane. Proteins destined for the degradative pathway are sorted from
the early endosome to the late endosomes and shuttled to the lysosome
for proteolysis. Having regard to the cell localization, htt could be impli-
cated in modulating all these biological events [37].
Thus, to study the impact of polyQ-htt on EGFR signaling and traf-
ﬁcking, we have used, as model, primary human HD ﬁbroblasts homo-
zygous for the HD gene because only expanded full-length human
polyQ-htt is expressed at endogenous level from its own promoter.
To evaluate EGFR fate in polyQ-htt expressing cells, we used differ-
ent approaches: quantiﬁcation of the levels of EGFR internalization
and degradation and measurement of EGFR synthesis and turnover. In
comparison with control cells, polyQ-htt expressing cells had not
down-expression, decreased phosphorylation and/or altered synthesis
of EGFR. On the contrary,we revealed delayed EGFR degradation and al-
tered trafﬁcking. EGFR degradation studies demonstrated that the life-
time of internalized EGFR is extended in cells expressing polyQ-htt, by
causing a delay in the exit of the receptor from an early endosome com-
partment en route to the degradative compartment. These novel ﬁnd-
ings could be explained by the lost of functional role for polyQ-htt as a
regulator of bidirectional motility of endosomal organelles [37]. More-
over, the inhibition of Rab11 activation by mutant htt with deﬁciency
in the recycling of biotin-transferrin receptor, found in another study,
Fig. 8. EGF receptor endocytosis and degradation in polyQ-htt ﬁbroblasts. Activation of the EGF receptor can result in receptor internalization through receptor-mediated endocytosis,
desensitizing further receptor signaling. From the early endosome, receptors can either be recycled back to the cell surface, or they can move through the late endosome to the lysosome for
proteolytic degradation. The sorting of receptors in the early endosome for degradation requires the tyrosine kinase activity of activated growth factor receptor, and involves ubiquitination
of the receptor. Targeting of receptors for degradation requires members of the Cbl gene family. Cbl proteins bind to tyrosine‐phosphorylated EGF receptor, and are E3 ubiquitination ligases
that label receptor for degradation. c-Cbl binds EGFR both directly via EGFR-SH2 domain interactions, and indirectly via a second adaptor protein, Grb2, which can interact also with huntingtin
protein [32,43]. Our results suggest that polyQ-htt interacting indirectlywith EGFR, throughGrb2 adapter, could block the EGFR ubiquitination and at the same time slacken endocytic pathway,
indicating that polyQ-htt is unable to coordinate bidirectional vesicle motility along the microtubule and actin cytoskeletons. This is in line with other reports showing that the associations of
EGF receptors with growth factor receptor-binding protein 2 (Grb2) is signiﬁcantly inhibited [32,43].
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somes back to the plasma membrane [8].
Parallel to the effects on endocytic trafﬁcking, polyQ-htt substantial-
ly suppressed the ubiquitination of activated EGFR. Reduced EGFR
ubiquitination, in turn, appears to correlate with suppressed recruit-
ment of c-Cbl, the E3 ligase that catalyzes EGFR ubiquitination. Indeed,
it is widely agreed that c-Cbl-binding to the receptor is critical for the
down-regulation and lysosomal degradation of activated EGFR [38]. In
addition, c-Cbl is required for the fusion of early endosomes that trafﬁc
EGFR to lysosomes [20]. As a result, tyrosine-phosphorylated EGFR
failed to transit to acidic lysosomes and was preserved in the cell for a
sustained period.
To establish whether polyQ-htt alters not only the EGFR ubiquitina-
tion but also the quality of EGFR polyubiquitination, EGFR ubiquitin
linkages were analyzed by ubiquitin-AQUA methodology. The results,
however, did not reveal signiﬁcant qualitative differences between
cells expressing polyQ-htt and the controls. These observations are
consistent with previous reports using the EGFR mutant Y1045F [39].
In contrast to the extended lifetime of the internalized EGFR, de-
creased signaling by the EGFR in cells expressing polyQ-htt was demon-
strated. We noted diminished levels of ERK1/2 phosphorylation in cells
expressing polyQ-htt following EGF stimulation. This effect was com-
binedwith a transient state of ERK1/2 phosphorylation. Again, this ﬁnd-
ingmight be explained on the basis of an altered EGFR trafﬁcking. Since
polyQ-htt strongly inhibit the EGFR redistribution from early to late
endosomes, it causes, as consequence, a decrease in the active ligand–receptor complexes present within the late endosomal compartment,
thought to be a vital prerequisite for EGF-stimulated Erk signaling
[40]. Indeed, recent studies have revealed a role for endocytic organ-
elles, particularly the late endosomal compartment, as signalling plat-
forms for the EGFR [41]. The inhibitory effect of EGF-stimulated Erk
signaling can at least in part account for the decrease in the migration
and proliferation that we have revealed in ﬁbroblasts expressing
polyQ-htt.
Finally, we found that polyQ-htt interacted with EGFR forming SDS-
resistant aggregates. The formation of a HMW complex between EGFR
and polyQ-htt can sequester EGFR and increase the perturbation of
EGFR trafﬁcking. Indeed, this post-translational modiﬁcation of EGFR
after interaction with the ligand in the presence of polyQ-htt might sig-
niﬁcantly impact on the EGF response, conditioning further the strength
and duration of the intracellular signaling cascade [38].
Thus, regulation of EGFR trafﬁcking is themeans bywhich htt exerts
its inﬂuence on EGF-stimulated cell behavior, and indicates that
polyQ-htt is unable to coordinate bidirectional vesicle motility along
the microtubule and actin cytoskeletons. According to our research it
appears that polyQ-htt, which interacts with EGFR, blocks not only its
ubiquitination but also its endocytic trafﬁcking (see Fig. 8 for our pro-
posed mechanistic model).
To our knowledge the data reported herein represent the ﬁrst sig-
naling and phenotypic characterization of polyQ-htt involvement in
the modulation of EGF stimulation in non-neuronal cells. Moreover,
it is possible that the described biological phenomena driven by
113M.A.B. Melone et al. / Biochimica et Biophysica Acta 1832 (2013) 105–113polyQ-htt are not peculiar to EGFR but rather represent a more gener-
al aspect of interference between huntingtin and other growth fac-
tors, such as the brain-derived neurotrophic factor (BDNF), that can
lead to decreased survival of neurons [2].
On the basis of our results, it might be rethink the pathogenesis of
some pathological ﬁndings present in HD patients not related to the
neurodegenerative disease, such as thinning of skin and poor wound
healing, so far considered aspects of hypothalamic–pituitary–adrenal
axis alterations in Huntington's disease [42].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.09.001.Acknowledgements
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